Literature DB >> 11482986

Elimination of the truncated message from the herpes simplex virus thymidine kinase suicide gene.

D Chalmers1, C Ferrand, J F Apperley, J V Melo, S Ebeling, I Newton, A Duperrier, A Hagenbeek, E Garrett, P Tiberghien, M Garin.   

Abstract

Introduction of the Herpes simplex virus thymidine kinase (HSV-tk) gene into target cells renders them susceptible to killing by ganciclovir (GCV). We are studying the use of HSV-tk-transduced T lymphocytes in the context of hematopoietic stem cell transplantation. We have previously shown, in vitro and in vivo, the occurrence of transduced cells resistant to GCV due to a deletion within HSV-tk. This deletion, a consequence of the presence of cryptic splice donor and acceptor sites, originates in the retroviral producer cell. Here we adopt two different methods that introduce third-base degenerate changes at the cryptic splice sites and so prevent splicing. Consequently, the HSV-tk protein is unaltered and the sensitivity of the target cells to GCV is preserved. The use of this mutated HSV-tk should reduce the likelihood of the development of resistant genetically modified cells during clinical trials.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11482986     DOI: 10.1006/mthe.2001.0433

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  10 in total

1.  Selective removal of undifferentiated embryonic stem cells from differentiation cultures through HSV1 thymidine kinase and ganciclovir treatment.

Authors:  Ortwin Naujok; Joanna Kaldrack; Terbish Taivankhuu; Anne Jörns; Sigurd Lenzen
Journal:  Stem Cell Rev Rep       Date:  2010-09       Impact factor: 5.739

2.  Cancer suicide gene therapy with TK.007: superior killing efficiency and bystander effect.

Authors:  Ellen Preuss; Alexander Muik; Kristoffer Weber; Jürgen Otte; Dorothee von Laer; Boris Fehse
Journal:  J Mol Med (Berl)       Date:  2011-06-23       Impact factor: 4.599

3.  Long-term treatment with valganciclovir improves lentiviral suicide gene therapy of glioblastoma.

Authors:  Jubayer A Hossain; Md A Latif; Lars A R Ystaas; Sandra Ninzima; Kristoffer Riecken; Arnaud Muller; Francisco Azuaje; Justin V Joseph; Krishna M Talasila; Jiwan Ghimire; Boris Fehse; Rolf Bjerkvig; Hrvoje Miletic
Journal:  Neuro Oncol       Date:  2019-07-11       Impact factor: 12.300

4.  Tomato thymidine kinase-based suicide gene therapy for malignant glioma--an alternative for Herpes Simplex virus-1 thymidine kinase.

Authors:  H Stedt; H Samaranayake; J Kurkipuro; G Wirth; L S Christiansen; T Vuorio; A-M Määttä; J Piškur; S Ylä-Herttuala
Journal:  Cancer Gene Ther       Date:  2015-01-23       Impact factor: 5.987

5.  Characterization of human T lymphocytes engineered to express interleukin-15 and herpes simplex virus-thymidine kinase.

Authors:  Cary Hsu; John D Abad; Richard A Morgan
Journal:  J Surg Res       Date:  2013-04-03       Impact factor: 2.192

6.  Quantitative analysis of clinically relevant mutations occurring in lymphoid cells harboring gamma-retrovirus-encoded hsvtk suicide genes.

Authors:  X Wang; M Olszewska; V Capacio; J Stefanski; M Przybylowski; S Samakoglu; A H Chang; M Sadelain; I Rivière
Journal:  Gene Ther       Date:  2008-06-19       Impact factor: 5.250

Review 7.  Prodrugs and prodrug-activated systems in gene therapy.

Authors:  Semira Sheikh; Daniel Ernst; Armand Keating
Journal:  Mol Ther       Date:  2021-04-06       Impact factor: 11.454

8.  Elimination of proliferating cells from CNS grafts using a Ki67 promoter-driven thymidine kinase.

Authors:  Vannary Tieng; Ophelie Cherpin; Eveline Gutzwiller; Alexander C Zambon; Christophe Delgado; Patrick Salmon; Michel Dubois-Dauphin; Karl-Heinz Krause
Journal:  Mol Ther Methods Clin Dev       Date:  2016-11-30       Impact factor: 6.698

Review 9.  Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies.

Authors:  Shangjun Sun; He Hao; Ge Yang; Yi Zhang; Yang Fu
Journal:  J Immunol Res       Date:  2018-04-17       Impact factor: 4.818

10.  The regulated long-term delivery of therapeutic proteins by using antigen-specific B lymphocytes.

Authors:  Katalin Takács; Camille Du Roure; Stephen Nabarro; Niall Dillon; John H McVey; Zoe Webster; Angus Macneil; István Bartók; Christopher Higgins; David Gray; Matthias Merkenschlager; Amanda G Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-01       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.